Back
Alopecia areata universalis elicited during treatment with adalimumab.
Journal article

Alopecia areata universalis elicited during treatment with adalimumab.

  • 2008-01-31
Published in:
  • Dermatology (Basel, Switzerland). - 2008
Adalimumab
Adult
Alopecia Areata
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arthritis, Psoriatic
Humans
Male
Psoriasis
Tumor Necrosis Factor-alpha
English Adalimumab is a fully humanized recombinant anti-tumour-necrosis-factor (TNF-alpha) monoclonal antibody which has been approved for rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis and Crohn's disease. We report a case of alopecia areata (AA) universalis occurring 6 months after administration of adalimumab monotherapy in a patient with a long-standing history of psoriatic arthritis and psoriasis. The diagnosis was confirmed by a scalp biopsy which showed a peribulbar infiltrate of both CD4+ and CD8+ T cells, CD1a+ dendritic cells as well as CD68+ and CD163+ macrophages. In addition, immunofluorescence staining for TNF-alpha was found in the mononuclear cell infiltrate. This case suggests a complex role of TNF-alpha in the induction of AA.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/143988
Statistics
Document views: 53 File downloads: